Evaluation of Immuknow assay for predicting the risk of infection and rejection in liver transplantation recipients in Hong Kong

Abstract

Background: Liver transplantation is a curative method for end-stage liver

diseases, small unresectable hepatocellular carcinoma and acute liver failure. The

discovery of immunosuppressive drugs increases the survival rate of liver

transplanted recipients by reducing the incidence of graft rejection. Several

complications such as renal dysfunction and increase risk of malignancy result

from life-long treatment of transplanted recipients with immunosuppressant. If

recipients are over-immunosuppressed, the risk of infection might be increased.

On the other hands, if recipients are under-immunosuppressed, the risk of

rejection would be increased. It should be useful if a test or a bio-marker that

could predict and differentiate infection and rejection in transplanted recipients.

Therefore, patients could be treated before adverse conditions. Although

therapeutic drug monitoring has been performed as a routine test, it is mainly

targeted for minimizing drug toxicity but little help in predicting infection and

rejection. A new assay named Cylex? Immuknow? assay is designed to measure

global cell mediated immunity of immunosuppressed population, by quantifying

the amount of ATP synthesis by CD4+ T cells in response to PHA stimulation. It is

undergoing evaluation in assessing the immune status of patients in order to

predict the risk of infection and rejection, and also other conditions. (1, 2)

Objectives: In this pilot study, we would like to evaluate ImmuKnow for

predicting the risk of infection and rejection in liver transplanted recipients in

Hong Kong.

Methods: Blood samples were collected from liver transplanted recipients at

different time intervals. The immune cell response of these patients was measured

by Immuknow assay. Patients with low immune response might have a high risk

of infection, patients with high immune response might have a high risk of

rejection, and patients with moderate immune response should be clinically stable.

Results and conclusion: Twenty-six blood samples were collected from eight

transplanted recipients. The average Immuknow assay value for the

post-transplant samples was 304.6 ng/mL ATP which represented moderate

immune cell response according to the interpretation table. (Table 3) This was

reasonable as the subjects were all clinically stable by well-controlled

immunosuppression. The result was consistent with other studies. (1, 3) However,

the association between low immune cell response and infection, and the

association between high immune cell response and graft rejection could not be

investigated as both of these conditions were not found in this pilot study. A larger

study including episodes of infection and rejection should be conducted in order

to evaluate the value of Immuknow assay more completely.